Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic #Psilocybin, Facilitating Entry into the International Market Read Press Release: https://t.co/Pp13j9Szzt

Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods Read Press Release: https://t.co/CDMwmjBIh0

Core One’s Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson’s Disease Read Press Release:

Core One Labs’, Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying #Psilocybin from Mushroom Biomass Read Press Release:

Core One’s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting #Alzheimer’s and #Parkinson’s Disease Read Press Release:

Core One Labs Enters into Letter of Intent for First Sale of its #Psychedelic Compounds Read Press Release:

Core One’s Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic #Psilocybin https://t.co/GiGONNQV1G

Core One’s Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic #Psilocybin Production Method https://t.co/ju0BQ1vYXJ

Core One in Talks with Multiple Companies to Supply #Psilocybin Read Press Release:

Core One Labs’ GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of #Psychedelic Prodrugs with Long-established Compounding Pharmacy Read Press Release:

Core One’s Awakened Completes Successful Synthetic Production of #Psilocin in its GMP Certified Manufacturing Facility Read Press Release:

Core One Labs’ Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on #psychedelics Drug Development to Combat a Variety of Neurological Diseases Read Press Release :

Core One Labs’ Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle #psychedelics Supply Chain Solution for Clinicians, Researchers and other Drug Developers Read Press Release:

Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities Read Press Release:

Core One Labs’ Akome Move #psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential Read Press Release:

Core One Labs’ Scientists Successfully Complete Breakthrough First Step in Producing API-Grade #DMT Read Press Release:

Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic #Psilocybin Read Press Release:

Core One Labs Applauds New Study Supporting #Psilocybin #Psychedelic Drug Therapy May Help Treat Alcohol Addiction Read Press Release:

Core One Labs Engages in Talks with GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic #Psilocybin Read Press Release:

Core One Labs’ Akome Achieves Another Milestone in Development of its #psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies Read Press Release: